It affects its downstream B-cell lymphoma 6 protein (BCL6), facilitating normal B-cell survival and lymphogenesis of B-cell non-Hodgkin lymphoma (NHL).141 Moreover, JMJD3 is involved in the treatment response to chemotherapies, with JMJD3 inhibitors demonstrating significant chemo-sensitization on B cells.139 Recently, a potential link was established between JMJD3 demethylase and cyclin-dependent kinase 9 (CDK9), the abnormal expression of which was a frequent event in DLBCL. Here, CDK9 is linked to B-cell non-Hodgkin lymphoma.